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Abstract Activation of the extracellular signal-regulated ki-
nases (ERKs) 1 and 2 is correlated to cell survival, but in
some cases ERKs can act in signal transduction pathways lead-
ing to apoptosis. Treatment of mouse ¢broblasts with 20 WM
etoposide elicited a sustained phosphorylation of ERK 1/2, that
increased until 24 h from the treatment in parallel with caspase
activity. The inhibitor of ERK activation PD98059 abolished
caspase activation, but caspase inhibition did not reduce ERK
1/2 phosphorylation, suggesting that ERK activation is placed
upstream of caspases. Both ERK and caspase activation were
blocked in cells depleted of polyamines by the ornithine decar-
boxylase inhibitor K-di£uoromethylornithine (DFMO). In eto-
poside-treated cells, DFMO also abolished phosphorylation of
c-Jun NH2-terminal kinases triggered by the drug. Polyamine
replenishment with exogenous putrescine restored the ability of
the cells to undergo caspase activation and ERK 1/2 phosphor-
ylation in response to etoposide. Ornithine decarboxylase activ-
ity decreased after etoposide, indicating that DFMO exerts its
e¡ect by depleting cellular polyamines before induction of apo-
ptosis. These results reveal a role for polyamines in the trans-
duction of the death signal triggered by etoposide. 7 2002
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1. Introduction
Mitogen-activated protein kinases (MAPKs) are fundamen-
tal components of the signalling pathways transducing extra-
cellular stimuli into a variety of cell responses [1]. The MAPK
subtypes are preferentially regulated by diverse groups of
extracellular stimuli. The classical MAPK cascade is activated
in response to mitogenic signals that operate through di¡erent
mechanisms, and results in the activation of the MAPK mem-
bers ERK 1 and ERK 2 (extracellular signal-regulated kinase
1 and 2, also called p44 and p42 MAPK) through phosphor-
ylation by the dual-speci¢city MAPK kinase MEK 1/2. Two
other distinct MAPK cascades have been characterized, lead-
ing to the activation of JNKs (c-Jun N-terminal kinases, also
called SAPKs, stress-activated protein kinases) and of p38
MAPKs respectively. These pathways, however are mainly
activated by cytokines and environmental stress and are gen-
erally linked to induction of apoptosis [2]. ERK activation has
an essential role in promoting cell cycle progression and ulti-
mately, cell proliferation [1]. ERK activation has been gener-
ally correlated to cell survival [3,4]. However, growing evi-
dence suggests that in some cases ERK can act in signal
transduction pathways leading to apoptosis [5^8].
Another class of molecules correlated to both cell growth
and cell death is represented by polyamines [9,10], and ac-
tually, evidence indicates a cross-talk between these organic
polycations and the MAPK pathway [11^13]. Polyamines are
absolutely required for cell proliferation, and the inhibition of
their biosynthesis represents a pharmacological tool in cell
growth control [9]. The role of polyamines in apoptosis is
complex. Excessive polyamine levels directly triggers apopto-
sis [14,15], but polyamine depletion can sensitize or protect
cells exposed to death triggers, depending on the pathway
engaged by the death stimulus [16,17].
Apoptosis is characterized by the activation of the caspase
proteases, that execute the death program [18]. Polyamine
synthesis is necessary for caspase activation by the apopto-
sis-inducing drug etoposide in transformed mouse ¢broblasts
[16]. In order to study the mechanism(s) underlying the poly-
amine requirement for etoposide-induced apoptosis, we exam-
ined the role of polyamines in signal transduction pathways
activated by etoposide. We found that etoposide elicited a
sustained activation of ERK 1/2, whose phosphorylation
was strongly correlated to caspase activation. Polyamine syn-
thesis was found to be necessary for these events, since both
ERK and caspase activation were blocked in cells depleted of
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polyamines by the ornithine decarboxylase (ODC) inhibitor
K-di£uoromethylornithine (DFMO)
2. Materials and methods
2.1. Materials and cells
Polyamines, acetyl-Asp-Glu-Val-Asp-amino-4-methylcoumarin (Ac-
DEVD-AMC), acetyl-Asp-Glu-Val-Asp-aldehyde (AcDEVD-CHO),
etoposide and all other biochemical reagents were products of Sigma
Chemical Company. Mouse monoclonal antibodies against caspase 3
and p53 were from Santa Cruz Biotechnology. Anti-ERK 1/2 and
anti-phospho-ERK 1/2 as well as anti-phospho-JNKs and anti-phos-
pho-p38 MAPK were from New England Biolabs. Horseradish per-
oxidase-conjugated anti-mouse IgG from Amersham was used as a
secondary antibody.
Transformed mouse embryo ¢broblasts were used. These cells were
chosen because they allowed the comparison with the corresponding
cells obtained from Gy mice that lack spermine being de¢cient in
spermine synthase [19]. Fibroblasts from normal and Gy mice were
derived from 14-day-old male embryos and immortalized by trans-
fection with a plasmid expressing SV40 large and small T antigens,
as described previously [19]. Cells were grown as described [16] in 10-
cm culture dishes in Dulbecco’s modi¢ed Eagle’s medium containing
pyruvate and pyridoxine (Gibco) supplemented with 2 mM glutamine,
10% fetal calf serum, 100 Wg/ml each penicillin and streptomycin, at
37‡C and 5% CO2. In all the experiments, cells were cultured for
2 days and then treated with etoposide for the time indicated. To
obtain polyamine depletion, the medium was added with 100 WM
DFMO from the seeding. Cell viability was evaluated by trypan
blue exclusion.
2.2. Caspase activity
The activity of caspase enzymes was measured by the cleavage of
the £uorogenic peptide substrate AcDEVD-AMC which represents a
substrate for caspase 3 and other members of the caspase family. At
the indicated time points, cells were washed in phosphate-bu¡ered
saline, harvested in 0.4 ml of lysis bu¡er [16] and subjected to two
cycles of freeze^thawing. The lysates were centrifuged for 10 min at
28 000g at 4‡C and the supernatant used to assay enzyme activity. 10
Wl of extract were incubated for 15 min at 37‡C in a ¢nal volume of 30
Wl to determine caspase activity as described [20]. One unit is de¢ned
as the amount of enzyme activity cleaving 1.0 nmol of substrate per
minute in the standard conditions described.
2.3. Western blotting
The determination of ERK 1/2 levels and phosphorylation was
performed as described [12]. Brie£y, cells were scraped in 0.4 ml of
lysis bu¡er and frozen/thawed twice. After centrifugation and dena-
turation of soluble proteins, cell proteins (40 Wg) were fractionated by
SDS^PAGE under reducing conditions (12% gel). After blotting, the
membranes were incubated overnight at 4‡C with the primary anti-
body anti-ERK 1/2 or anti-phospho-ERK 1/2 followed by incubation
for 1 h with secondary antibody. Immunoreactive bands were visual-
ized by chemiluminescence. The proteolytic processing of caspase 3
was detected in ¢broblasts grown for 48 h and then exposed to etopo-
side for 24 h exactly as described [16]. Also, the p53 level was assayed
by Western blotting and immunodetection [20].
2.4. Polyamine analysis and ODC assay
Cells were grown for 48 h, then were washed twice with phosphate-
bu¡ered saline, harvested in 0.4 ml of chilled 0.3 M perchloric acid
and subjected to two cycles of freeze^thawing. After centrifugation at
12 000g for 5 min at 4‡C, 0.3 ml of the clear supernatant was used
for polyamine analysis, whereas the pellet was dissolved in 0.4 ml of
0.3 M NaOH for protein determination.
Polyamines were separated and quanti¢ed by high performance liq-
uid chromatography after derivatization with dansyl chloride [15].
ODC activity was measured by estimation of the release of 14CO2
from radiolabelled ornithine [12]. One unit catalyzes the decarboxyla-
tion of 1 nmol of ornithine per minute.
3. Results
3.1. Etoposide triggers ERK 1/2 phosphorylation
Etoposide is an inhibitor of topoisomerase II widely used in
cancer chemotherapy that can induce apoptosis in a variety of
cell types [21]. Similar to several other pharmacological or
environmental stresses, etoposide-induced apoptosis is accom-
panied by activation of JNKs [22]. To investigate whether
etoposide-induced apoptosis is also accompanied by changes
in ERK activation, activated ERK 1 and ERK 2 were assayed
by immunoblotting using an antibody that speci¢cally recog-
nizes the active, phosphorylated forms of both kinases. As
seen in Fig. 1A, treatment of transformed embryo mouse ¢-
broblasts with 20 WM etoposide for 24 h, caused a marked
increase in the phosphorylation of ERK 1/2, as seen by the
large increase in the bands corresponding to p44 (ERK 1) and
p42 (ERK 2). In order to demonstrate uniform loading of gels
and to exclude possible e¡ects of etoposide on ERK expres-
sion, the blots were reprobed with an anti-ERK antibody that
recognizes both ERK 1 and ERK 2. There was no change in
the amount of either ERK 1 or ERK 2 indicating that the
increase in the amount of activated ERKs did not result from
change in the amount of the ERK proteins.
Under the same conditions, etoposide induced the process-
ing of the e¡ector procaspase 3 (Fig. 1A), that represents a
crucial point in apoptosis [18]. The proteolytic processing of
procaspases into active caspases determines the onset of their
enzymatic activity, and actually, caspase activity increased
over the time reaching a maximum after 24 h from etoposide
treatment (Fig. 1B). The levels of phospho-ERK 1/2 also con-
tinued to increase over the time course of the experiment,
accompanying the increased caspase activity. No further in-
crease in caspase activity or ERK 1/2 phosphorylation was
detected at later time points (not shown).
Fig. 1. Activation of caspase 3 in etoposide-treated ¢broblasts is ac-
companied by the phosphorylation of ERK 1/2. A: Mouse ¢bro-
blasts were incubated for 24 h with 20 WM etoposide. Cell extracts
(40 Wg of proteins) were analyzed by Western blotting using speci¢c
antibodies for total ERK 1/2, or phosphorylated ERK, or caspase
3. B: Following treatment with 20 WM etoposide, the cells were har-
vested at the indicated time points for the determination of ERK
1/2 phosphorylation and caspase activity (meanPS.E.M., n=3).
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The parallel time course suggested a correlation between
caspase and ERK 1/2 activation. In order to assess a possible
role of ERK 1/2 in the apoptotic response to etoposide and to
determine whether it precedes or follows active caspases, in-
hibitors of ERK phosphorylation or caspase activity were
used. Firstly, we tested the e¡ect on etoposide-induced cas-
pase activation of the speci¢c MEK inhibitor PD98059 [23],
which has been widely used to block ERK 1/2 activation. Fig.
2A shows that treatment of ¢broblasts with 50 WM PD98059
given together with etoposide abolished the increase in cas-
pase activity, the e¡ect being similar to that obtained with 100
WM AcDEVD-CHO, an inhibitor of e¡ector caspases 3, 6,
and 7 [24]. On the other hand, AcDEVD-CHO treatment
did not result in any reduction in the magnitude of ERK
1/2 activation, as assessed by the phospho-speci¢c ERK 1/2
antibody (Fig. 2B). These results suggest that ERK 1/2 acti-
vation lies upstream of caspase activation. It is worth noting
that the inhibition of p38 MAPK activity with SB203580 and
of protein kinase C with chelerythrine did not protect the cells
from caspase activation, whereas only a slight inhibition was
obtained with 1 WM of both D and L isomers of the cell
permeable JNK peptide inhibitor JNKI1 [25].
3.2. Polyamine depletion inhibits ERK 1/2 phosphorylation and
caspase activation in etoposide-treated ¢broblasts
Polyamine depletion obtained by the ODC inhibitor
DFMO abolishes caspase activation triggered by etoposide
in the current experimental model [16], establishing a neces-
sary role for polyamines in etoposide-induced apoptosis. To
assess if polyamine depletion can also interfere with the path-
way resulting in ERK 1/2 phosphorylation or is placed down-
stream of this step, the ¢broblasts were incubated for 2 days
in the presence of 100 WM DFMO to deplete cellular poly-
amines, then were treated with etoposide. This pretreatment
with DFMO by itself increased ERK 1/2 phosphorylation
very slightly, but completely inhibited the strong e¡ect of
etoposide on ERK 1/2 activation (Fig. 3A). In accordance
with the experiments reported in Fig. 2, inhibition of ERK
1/2 phosphorylation was coupled to inhibition of caspase 3
activation. Actually, in polyamine-depleted cells, etoposide
treatment could not result in processing of procaspase 3.
The inhibition of caspase activation in DFMO-treated cells
was independent of etoposide dosage and was similar even
when the drug concentration was ¢ve-fold higher than the
usual one (not shown).
Lee et al. reported evidence for activation of the MAPK
cascade in response to p53 expression [26]. Since etoposide-
induced apoptosis may be related to p53, at least in some cells
[20,27], and DFMO reportedly in£uences p53 level [28], the
e¡ect of polyamine depletion on p53 expression was studied.
The cells were harvested at various times (2^24 h) after etopo-Fig. 2. E¡ect of caspase and kinase inhibitors on caspase activity in
etoposide-treated ¢broblasts. A: Mouse ¢broblasts pretreated for 30
min with 200 WM AcDEVD-CHO (inhibitor of caspase 3 and other
e¡ector caspases), or PD98059 (50 WM), or 1 WM of both D- and
L-JNK1, or SB203580 (10 WM), or chelerythrine (5 WM), were then
incubated for 24 h with 20 WM etoposide. The cells were then col-
lected to measure caspase activity digesting the peptide substrate
Ac-DEVD-AMC. Data are meansPS.E.M. of three determinations.
B: Fibroblasts were treated with 20 WM etoposide in the absence or
presence of 200 WM AcDEVD-CHO for 24 h. Cells were harvested,
and ERK phosphorylation was examined in extracts by Western
blotting using anti-phospho-ERK 1/2 antibody.
Fig. 3. E¡ect of polyamine depletion on caspase 3 activation, ERK
and JNK and p38 phosphorylation, and p53 level in etoposide-
treated ¢broblasts. The cells were grown for 48 h after plating in
the absence or presence of 100 WM DFMO, then were treated with
20 WM etoposide for further 24 h. Cells were harvested and cell ex-
tracts obtained. A: 40 Wg of proteins in cell extracts were analyzed
by Western blotting using speci¢c antibodies for caspase 3, total
ERK 1/2, phosphorylated ERK, or p53. B: The phosphorylation of
JNK and p38 was examined by Western blotting using antibodies
speci¢c for the phosphorylated proteins.
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side treatment, and p53 level was determined. The p53 protein
was detectable even in control untreated cells, however neither
etoposide nor DFMO elicited any signi¢cant e¡ect on its ex-
pression at any time point (Fig. 3 shows p53 levels measured
6 h after etoposide).
DFMO also inhibited the phosphorylation of p46 and p54
JNK proteins as well as the slight increase in p38 MAPK
phosphorylation that follows etoposide treatment (Fig. 3B).
In some experimental models, the induction of ODC that
follows apoptotic treatments has been proposed to be actively
involved in the activation of apoptosis [29,30]. However, in
mouse ¢broblasts etoposide did not induce ODC, whose ac-
tivity was actually suppressed when the cells underwent apo-
ptosis (Fig. 4). Furthermore, in preliminary experiments we
observed that if DFMO was given together or immediately
before etoposide, its inhibiting e¡ect on both caspase and
ERK activation was lost (not shown). These data indicate
that the e¡ect of DFMO is caused by depletion of cellular
polyamines, which must be low at the beginning of the treat-
ment with the inducer of apoptosis.
Fig. 5A shows the polyamine content in ¢broblasts prein-
cubated 2 days with DFMO, i.e. the polyamine level when
etoposide is added. At the dosage used (100 WM), DFMO
caused maximal reduction in putrescine and spermidine levels,
and no further reduction was obtained with the higher con-
centrations of the drug generally used (5^10 mM). Putrescine
decreased from 3.4 nmol/mg of protein to an undetectable
level (less than 0.4 nmol/mg), while spermidine was decreased
by about 80%. However, as it is characteristic for this drug,
DFMO did not a¡ect spermine content. This observation sug-
gests that in the whole cell, spermine does not have a neces-
sary role in the permissive e¡ect of polyamines on ERK 1/2
phosphorylation that follows etoposide treatment. This con-
clusion was con¢rmed by the completely similar e¡ects of
etoposide on ERK 1/2 phosphorylation in normal ¢broblasts
and in the corresponding cells obtained from a Gy mouse that
lack spermine, being de¢cient in spermine synthase [19] (not
shown). Addition of 100 WM putrescine to DFMO-treated
¢broblasts completely restored polyamine content, as well as the ability of the cells to undergo caspase activation and ERK
1/2 phosphorylation in response to etoposide (Fig. 5B). In the
absence of etoposide, replenishment of polyamine level by
addition of putrescine to DFMO pretreated cells did not in-
£uence at all either ERK phosphorylation or caspase activity
(not shown).
4. Discussion
MAPK cascades participate in diverse cellular functions
such as cell growth, cell di¡erentiation, and cell death. The
ERK components of the MAPK family are involved in signals
triggered by growth factors-stimulated receptor tyrosine ki-
nases as well as by serpentine and cytokine receptors. All
these signals generally lead to RAS activation that couples
them to ERK activation [1,2].
The ERK pathway plays an essential role in promoting cell
cycle progression and is generally involved in proliferative
signaling and cell survival [1^4]. In contrast, JNKs and p38
MAPK, the other members of the MAPK family, are mainly
activated by extracellular stress signals and involved in apo-
ptosis [2,31]. Recently several reports have shown that the
original model postulating that stress-activated pathway is
related to apoptotic cell death, whereas the ERK pathway
Fig. 4. Etoposide decreases ODC activity in mouse ¢broblasts. The
cells were treated with 20 WM etoposide. At the time indicated, the
¢broblasts were harvested and cell extracts were assayed for ODC
and caspase activities. Results are meansP the range obtained in
two separate experiments.
Fig. 5. Polyamine replenishment restores caspase activation and
ERK phosphorylation in DFMO- and etoposide-treated ¢broblasts.
The cells were grown for 48 h after plating without any addition
(Ctrl), or in presence of 100 WM DFMO, or in presence of 100 WM
DFMO plus 100 WM putrescine (DFMO+Put), then (A) cells were
harvested and polyamines were determined in acid extracts by high
performance liquid chromatography (spm, spermine; spd, spermi-
dine; put, putrescine); B: cells were treated with 20 WM etoposide
for 24 h before the preparation of extracts for the determination of
caspase activity and ERK phosphorylation. In both panels results
are meansPS.E.M. of three determinations.
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protects the cells from apoptosis, is a simplistic one. A grow-
ing body of literature has demonstrated that ERK 1/2 activa-
tion does not necessarily deliver a survival signal, but itself
can be correlated to induction of apoptosis in some contexts
[5^8]. Actually, activation of all the MAPK pathways, includ-
ing ERK, JNK and p38 pathways, may be present during
apoptosis [2,31]. The stimulatory or inhibitory e¡ect of these
pathways depends on the cell type and the apoptotic trigger.
Furthermore, even the timing of MAPK activation is thought
to be important in the cell decision to die [5].
Previous studies have demonstrated an activation of JNK in
response to etoposide [22], even if the actual role of such
activation is not clear [32]. In mouse ¢broblasts, etoposide
induces phosphorylation of JNK enzymes, whereas the phos-
phorylation of p38 MAPK is hardly a¡ected. However, in
these cells, etoposide also triggers a sustained phosphorylation
of both p42 and p44 ERK proteins that, on the basis of
inhibitor studies shown in Fig. 2, has a predominant role in
induction of apoptosis. ERK 1/2 phosphorylation is not a
rapid and transient event, as in the case of the response to
mitogenic stimuli, but it appears 2^4 h after the drug and
continues to increase until 24 h. The ability of the MEK
inhibitor PD98059 [23] to prevent the increase in caspase ac-
tivity triggered by etoposide suggests that ERK 1/2 activation
functions upstream of these proteases. This view is supported
by the e¡ect of the inhibitor of e¡ector caspases AcDEVD-
CHO [24], which blocks caspase activity without interfering
with ERK 1/2 phosphorylation.
The molecular events linking the primary e¡ect of etopo-
side, generally thought to be the interaction with topoisomer-
ase II [21], with induction of apoptosis, represented by caspase
activation triggered by cytochrome c exit from mitochondria
[33], are largely unknown. We have shown that ERK 1/2
phosphorylation is one of these events. Also polyamines are
important in the early phases of etoposide-induced apoptosis
and actually etoposide cytotoxicity [34] and caspase activation
[16] are attenuated in cells depleted of polyamines by pretreat-
ment with the ODC inhibitor DFMO. Furthermore, ERK 1/2
phosphorylation is abrogated in polyamine-depleted cells sug-
gesting that polyamines are required at a stage upstream ERK
1/2 activation that, in turn, precedes caspase activation.
As regards the possible mechanism of the inhibiting e¡ect
of polyamine depletion on etoposide-induced ERK activation
and caspase activation, we have examined some possible tar-
gets. Firstly, the cytoprotective action of DFMO is not caused
by interference with p53 expression, that in some cell systems
can be in£uenced by etoposide [27], ERK [26], or DFMO [28].
Actually, in our experimental model, neither etoposide nor
DFMO in£uence the p53 level (Fig. 3A). Possibly, the lack
of p53 response may be brought about by the fact that the
mouse ¢broblasts used in our experiments were immortalized
using a plasmid expressing SV40 large and small T antigens
[19] that can interfere with p53 function [35]. Second, etopo-
side [36] and DFMO [37] in£uence polyamine transport, that
in turn may a¡ect the multidrug resistance (MDR) transporter
[38], responsible of extrusion of cytotoxic drugs from the cell.
However the inhibiting e¡ect of DFMO was maintained even
at very high concentration of etoposide, excluding an interfer-
ence with MDR transporter. Third, since ODC activity is
largely decreased after etoposide, a change in this enzyme is
not involved in induction of apoptosis, and the e¡ect of
DFMO cannot be ascribed to an inhibition of polyamine ac-
cumulation that follows the treatment with the inducer of
apoptosis [29]. Fourth, polyamine depletion can also induce
nuclear factor-UB (NF-UB) activation [39], that in turn can
in£uence polyamine metabolism [40] and protect the cells
against apoptosis [39,41]. However, in preliminary experi-
ments we found that in ¢broblasts etoposide itself could cause
a weak NF-UB activation that was hampered by DFMO (un-
published data).
Our results show that an early event triggered by etoposide
and leading to phosphorylation of the MAPK members ERKs
and JNKs is blocked in polyamine-depleted cells. Polyamines
could be required for signal transduction leading to MAPK
activation, or for the activity of topoisomerase II, that is
important for etoposide action [42], or could act by a¡ecting
the cellular localization of members of the Bcl-2 family [43].
Another possible model that we hypothesize is correlated to
the established role of polyamines in cell proliferation [9]. It is
known that the sensitivity to etoposide cytotoxicity depends
on the cell cycle [44] and is increased in transformed cells [45].
Actually, ERK activation is part of a proliferative pathway,
while growth arrest is a characteristic of cytotoxic drugs. The
generation of two con£icting signals by etoposide could lead
to apoptosis as hypothesized in di¡erent experimental systems
in which an imbalance between growth and arrest signals
occurs [5,7]. On the other hand, polyamine-depleted cells are
‘frozen’ in a non-proliferative status, avoiding the engagement
of pathways that can in£uence cell growth, such as the di¡er-
ent MAPK pathways. As a consequence, there is no genera-
tion of con£icting signals, and the way leading to caspase
activation is interrupted.
Finally, this experimental model suggests a need for caution
when polyamines are chosen as chemotherapeutic target and
polyamine synthesis inhibitors are used against cancer cells,
since polyamine depletion can reduce the ability of chemo-
therapeutic drugs to trigger apoptosis.
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